logo-loader
RNS
OptiBiotix Health PLC

OptiBiotix Health - SlimBiome® study in European Journal of Nutrition

RNS Number : 2784M
OptiBiotix Health PLC
11 June 2025
 

 

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

New SlimBiome® study published in European Journal of Nutrition

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, announces the publication of a new peer-reviewed study on SlimBiome® in the European Journal of Nutrition.  The European Journal of Nutrition is a peer reviewed, international journal that has a high impact factor with its articles widely cited and influential in its field.

 

The double-blind placebo-controlled study, led by Adele Costabile, Professor of Clinical Nutrition and the Microbiome at the University of Roehampton, found a single 3g dose of SlimBiome significantly reduced insulin levels, hunger, and the desire to eat whilst increasing the feeling of fullness. These are key factors in appetite regulation and the study conclusion highlights the potential of SlimBiome® as a non-pharmaceutical  approach to weight management. Prof Costabile will present her findings at the  18th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health being held on  24-26 June 2025.

 

These findings on the impact of a single dose of SlimBiome® are consistent with other published studies, consumer studies, and customer feedback which have shown SlimBiome® reduces hunger and food cravings leading to users both reducing the amount of food and the type of food they eat, leading to more sustainable weight management.

 

The study was carried out to support health claims for appetite regulation and hunger control in products of one of the USA's leading weight management brands (see announcement on 15 April 2025). Scientifically substantiated health claims help to differentiate SlimBiome® from other products on the market. OptiBiotix now has acute and long-term studies in healthy, overweight, and obese individuals which have allowed the Company to make on pack health claims in Europe, Australia/New Zealand, India, Asia, Canada, and the USA leading to agreements and multiple product launches with major international and national companies and brands (e.g Morepen, Muscletech, Myprotein). In the changing landscape of this market, brought about by the anti-obesity drugs, traditional approaches to weight management are being replaced by science backed products which provide functional benefits such as reduced hunger and desire to eat. SlimBiome® meets this developing trend. 

 

The University of Roehampton has published a press release which is set out below in Appendix I.

 

Stephen O'Hara, CEO of OptiBiotix Health plc commented: "We are really pleased to see this study published in such a well-respected journal.  The study adds further evidence to demonstrate the efficacy of SlimBiome® in reducing hunger and food cravings leading to changes in the amount and type of food people eat. Whilst the anti-obesity drugs have strong risk-benefits in the 16%* of the world adult population who are obese, they may not be the best choice for the 43%* who are overweight. SlimBiome® represents a natural alternative, particularly for overweight individuals, and has been widely used with no reported adverse side effects".

*See WHO report  Obesity and overweight

 

The Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive


 


Peterhouse Capital Limited (Broker)

Tel: 020 7220 9797

Duncan Vasey / Lucy Williams




Walbrook PR Ltd


Anna Dunphy

Mob: 07876 741 001

 

 


 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

 

Appendix I

 

 

University of Roehampton London

New Research by the University of Roehampton

 

New study suggests there may be another option to anti-obesity drugs

 

A new peer-reviewed study published today (10 June 2025) in the European Journal of Nutrition has found that a mineral-enriched prebiotic fibre complex may offer a safe and effective alternative for individuals seeking to manage their weight.

 

While anti-obesity medications can be effective for those with clinical obesity, they often come with significant side effects and were developed for cases where the risk-benefit trade-off is more clearly justified. For individuals who fall into the overweight or high-normal BMI range, this supplement could provide a better, non-pharmaceutical option for supporting healthy weight management.

 

The study, led by Adele Costabile, Professor in Clinical Nutrition and the Microbiome at the University of Roehampton, found that the mineral-enriched fibre supplement known as SlimBiome® significantly reduced post-meal insulin levels, decreased hunger by up to 37%, and increased feelings of fullness by up to 55% in healthy adults.

 

In a double-blind, placebo-controlled, randomised crossover trial, normal-weight participants were given either the supplement or a standard dextrose drink. The results were striking: participants who consumed the fibre complex reported significantly lower hunger (p=0.038), reduced desire to eat (p=0.002), and greater satiety (p=0.021) for over two hours post-ingestion compared to the placebo. They also showed a marked reduction in insulin levels at 45, 75, and 90 minutes after a glucose load, suggesting the supplement may help regulate metabolic responses to food. These factors are important in managing calorie intake.

 

Prof Costabile will present her findings at the 18th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health - IPC2025, 24-26 June 2025.

 

With 64.5% of adults in England now classified as overweight or obese - a 22.6% increase since 2015 - and weight-related conditions including type 2 diabetes, heart disease and some cancers placing a growing burden on the NHS, the search for sustainable, non-pharmaceutical weight management tools is increasingly urgent.

 

"Most diets rely on willpower alone and often fail," said Professor Costabile. "Our studies show that SlimBiome, a mineral-enriched prebiotic fibre complex, can reduce hunger and food cravings, offering a natural and scientifically backed option to anti-obesity drugs. Appetite regulation is a crucial part of weight control, and this supplement may help improve long-term success without harsh side effects."

 

The SlimBiome formulation, developed and patented by OptiBiotix Health, combines glucomannan (a viscous plant fibre), fructooligosaccharides (FOS, a prebiotic), and chromium (a trace mineral involved in insulin signalling) to target multiple mechanisms. These include delayed gastric emptying, improved blood sugar control, and gut microbiome modulation - factors that collectively contribute to appetite regulation and metabolic health.

 

"While further studies are needed to assess long-term outcomes, our findings indicate that combining fibre, prebiotics and trace minerals can support healthy weight management and glycaemic control - without risking losing muscle mass or causing gastrointestinal distress", said Professor Costabile. "In fact, participants only lost fat, not muscle mass, and showed improvements in gut microbiome diversity - including increases in beneficial bacteria known to influence satiety signals."

 

The combination of the three key ingredients is unique. Glucomannan, a plant-based fibre, acts to form a viscous gel in the stomach, slowing digestion and carbohydrate absorption. FOS supports the growth of beneficial gut bacteria, such as Bifidobacterium spp., which are known to promote the release of short-chain fatty acids that influence appetite-regulating hormones. Chromium, a trace mineral known to play a role in insulin signalling, acts in combination with the other minerals to moderate insulin responses.

 

Co-investigator of the studies, Dr. Michael Patterson of the University of Roehampton, said: "Pharmaceuticals that mimic appetite-suppressing gut hormones are a major advance, but not everyone can tolerate them. Prebiotics, such as SlimBiome, may stimulate the body's natural gut hormones, providing a gentler yet effective approach to appetite regulation. These findings align with earlier trials demonstrating reduced food intake and cravings over a four-week supplementation period."

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABLGDLXDBDGUG
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

8 min read